PMA device
Oncomine Dx Express Test
Life Technologies Corporation · Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System (PQP, Class III) · First FDA decision Jul 2, 2025, newest Sep 9, 2026Cancer detection and genomic testing
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
0
Naming "Oncomine Dx Express"
MAUDE reports
1
Brand "Oncomine Dx Express", since 2015
PubMed studies
5
Mentioning "Oncomine Dx Express"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Oncomine Dx Express Test
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- Oncomine Dx Express TestPMA supplement
P240040-S005 · Decided Sep 9, 2026 · 180 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
- Oncomine Dx Express TestPMA supplement
P240040-S002 · Decided Oct 15, 2025 · 75 days after receipt · Normal 180 Day Track No User Fee
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
P240040 · Decided Jul 2, 2025 · 232 days after receipt
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40210Palmetto GBAUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40278WPS Insurance CorporationUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40226CGS Administrators, LLCUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40222Noridian Healthcare Solutions, LLCUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40278WPS Insurance CorporationUpdated Sep 15, 2025
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40222Noridian Healthcare Solutions, LLCUpdated Aug 22, 2025
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40226CGS Administrators, LLCUpdated Aug 21, 2025
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40210Palmetto GBAUpdated Aug 18, 2025
Clinical trials
Device studies on ClinicalTrials.gov that name "Oncomine Dx Express", any status and sponsor, newest update first.
No registered device study names "Oncomine Dx Express".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Oncomine Dx Express", and for the whole product code for context.
This brand
1 reports: 1 malfunction, 0 injury, 0 death
Whole product code PQP
14 reports: 11 malfunction, 2 injury, 0 death
Newest reports for this brand
- ONCOMINE¿ DX EXPRESS TESTMalfunction
3003335080-2026-00001 · Received May 13, 2026 · Event dated May 11, 2026
Device type: Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System (PQP)
Device problem as coded: False Negative Result
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Oncomine Dx Express"[tiab]. The summary above synthesizes these.
- European Real-World Assessment of the Clinical Validity of a CE-IVD Panel for Ultra-Fast Next-Generation Sequencing in Solid Tumors.
Normanno N, Machado JC, Pescarmona E, et al. · Int J Mol Sci · 2023Multicenter Study
- Analytical and Clinical Validation of the Oncomine Dx Express Test, an In Vitro Diagnostic-Labeled Assay, for Genomic Profiling of FFPE Tumor Samples.
Cheng A, Nallu S, He L, et al. · Mol Diagn Ther · 2026
- First experiences in a US clinical laboratory with Oncomine Dx Express Test: Evaluation in formalin-fixed paraffin-embedded tissues.
Weaver A, Diercks A, Corral A, et al. · Mol Cell Probes · 2026
- The Genomic Landscape of Romanian Non-Small Cell Lung Cancer Patients: The Insights from Routine NGS Testing with the Oncomine Dx Target Panel at the PATHOS Molecular Pathology Laboratory.
Gaal OI, Ungureanu A, Pop B, et al. · Cancers (Basel) · 2025
- Analytical and clinical validation of Ion Torrentࡊ Oncomineࡊ Dx Express Test for identifying PIK3CA/AKT1/PTEN-altered tumors in patients with hormone receptor-positive advanced breast cancer for treatment with capivasertib.
Elvidge C, Heung M, Clark T, et al. · Transl Oncol · 2026
Other devices of this type
Also filed under product code PQP.
- FoundationOne CDxFoundation Medicine, Inc. · PMA 2026
- FoundationOne Liquid CDxFoundation Medicine, Inc. · PMA 2026
- Oncomine Dx Target TestLife Technologies Corporation · PMA 2025
- Guardant360 CDxGuardant Health, Inc. · PMA 2026
- xT CDxTempus AI, Inc. · PMA 2026
- TruSight Oncology ComprehensiveIllumina, Inc. · PMA 2026
- FoundationOne®Liquid CDxFoundation Medicine, Inc. · PMA 2026
- FoundationOneCDx (F1CDx)Foundation Medicine, Inc. · PMA 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.